Gingivitis comment deadline
This article was originally published in The Tan Sheet
Executive Summary
FDA should extend the deadline for comments on draft guidance for OTC gingivitis drug products from Aug. 29 to Oct. 28, the Consumer Healthcare Products Association requests in a July 15 submission to the agency. The extra 60 days will allow time "to coordinate an industry response and to provide the agency with meaningful and substantive comments," CHPA says. The draft guidance, published June 28, focuses on clinical trials design issues for OTC and Rx gingivitis treatments (1"The Tan Sheet" July 4, 2005, In Brief)...
You may also be interested in...
FDA gingivitis guidance
OTC gingivitis products should carry the labeling claim "helps prevent gingivitis" while Rx drugs may include the more scientific phrase "reduction of disease incidence," FDA recommends in a FDL-1draft guidance published in the Federal Register June 28. "Gingivitis: Development & Evaluation of Drugs for Treatment or Prevention" focuses on trial design issues and clinical assessments involved with developing both Rx and OTC products for the condition. Recommended inclusion criteria for clinical trials such as "a specified number of teeth present" and "a qualifying baseline plaque index" are provided by the agency, while exclusion criteria include "chronic disease with concomitant oral manifestations." A definition of the difference between prevention and treatment of the condition also is included...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.